Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GE Aerospace (GE) vs Incyte Corporation (INCY) Price & Performance

GE AerospaceTrade
Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

GE Aerospace vs Incyte Corporation — how do they compare? GE Aerospace trades at $365.15 (market cap $381.89B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: GE Aerospace is far larger — about 15.6× Incyte Corporation's market cap, and GE Aerospace pays a 0.51% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

GEINCY
Market Cap
$381.89B$24.54B
Sector
IndustrialsHealth
52-Week High
$381.22$129.93
52-Week Low
$265.93$81.61
Enterprise Value
$391.70B$20.04B
Dividend Yield
0.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GE Aerospace

GE Aerospace trades at $366.70, down 0.91% with bullish technical momentum and strong fundamental performance. The stock shows robust earnings beats in recent quarters with Q2 2026 EPS of $2.02 exceeding expectations of $1.86. Revenue growth accelerated to $45.86 billion in 2025 with net income margin improving to 17.72%. Analyst consensus remains strongly positive with 24 buy ratings and a $414.11 price target, representing 13% upside potential.

The outlook remains favorable with strong aerospace demand, defense contract wins, and expanding order backlog driving growth. Key risks include elevated valuation multiples (P/E 43.4, P/S 7.68) and potential execution challenges amid heavy investment in MRO and manufacturing expansion. The company's improving cash flow generation and strategic positioning in commercial engines and defense sectors support continued upside potential.

Incyte Corporation

Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.

The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.

Returns comparison

Trailing returns across standard periods

About GE Aerospace

General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.

Read more on GE

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY